it may be time to explore a different path. The LATITUDE Psoriasis OLE Study is evaluating an investigational oral treatment (pill) for adults with moderate to severe plaque psoriasis.
What if you could potentially impact the 125 million people worldwide (2–3% of the entire population) with psoriasis?1 Embrace the future of psoriasis care with the LATITUDE Psoriasis Studies.
Participation in clinical research for psoriasis could have an impact on 125 million people worldwide (2-3% of the entire population) with psoriasis.1 Embrace the future of psoriasis care with the LATITUDE Psoriasis OLE Study.
Learn more about the importance of clinical research in finding treatment options for psoriasis in the video below.
Embrace the future of psoriasis care with the LATITUDE Psoriasis OLE Study. This study is evaluating an investigational oral treatment (pill) for adults with moderate to severe plaque psoriasis.
The investigational treatment is thought to work by helping to control inflammatory signals known to contribute to the buildup of plaque psoriasis. All study treatments will be given as oral pills.
Participants who join the OLE after completing a previous LATITUDE Psoriasis Study will receive the investigational treatment daily for up to approximately 156 weeks. Participants who have not completed a previous LATITUDE Psoriasis Study will receive the investigational treatment daily for up to approximately 217 weeks.
Neither participants nor the study staff will know if participants are receiving the investigational treatment, the approved oral treatment, or a placebo. Participants will attend up to 20 scheduled study visits over the course of about a year.
We use cookies to optimize site functionality and give you the best experience. Necessary cookies enable core functionality. The website cannot function properly without these cookies and can only be disabled by changing your browser preferences.
For more detailed information on the cookies we use, please check our Privacy Policy.
By continuing to access this website, you are giving us consent to collect cookies.